Biofrontera AGBIFRF 58 Days Inventory is 472.66 as of Mar. 2026, which is 8% above its 10-year median of 438.45. GuruFocus rates BIFRF with a GF Score™ of 58/100 and a GF Value™ of $31.34. The stock has 4 warning signs investors should review. Among 918 Drug Manufacturers companies, Biofrontera AG ranks worse than 96.84% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Biofrontera AG's Average Total Inventories for the
three
months ended in Mar. 2026 was $4.25 Mil. Biofrontera AG's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.82 Mil.
Hence, Biofrontera AG's Days Inventory for the
three
months ended in Mar. 2026 was 472.66.
The historical rank and industry rank for Biofrontera AG's Days Inventory or its related term are showing as below:
BIFRF'
s Days Inventory Range Over the Past 10 Years
Min: 271.11 Med: 438.45 Max: 937.65
Current: 634.4
During the past 13 years, Biofrontera AG's highest Days Inventory was 937.65. The lowest was 271.11. And the median was 438.45.
BIFRF's Days Inventory is ranked worse than 96.84% of 918
companies
in the Drug Manufacturers industry
Industry Median: 164.43
vs BIFRF: 634.40
Biofrontera AG's Days Inventory
declined
from Mar. 2025 (809.34) to Mar. 2026 (472.66).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Biofrontera AG's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.19.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biofrontera AG's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.99.
Biofrontera AG (OTCPK:BIFRF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Biofrontera AG's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biofrontera AG's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Biofrontera AG Days Inventory Related Terms
Biofrontera AG Days Inventory Historical Data
* Premium members only.
The historical data trend for Biofrontera AG's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIFRF vs ZTS, UTHR, VTRS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera AG Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Days Inventory distribution charts can be found below:
* The bar in red indicates where Biofrontera AG's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofrontera AG (BIFRF) has a Days Inventory of 472.66 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Biofrontera AG and its competitors. This is near median its historical median of 438.45. Over the past decade, Biofrontera AG's Days Inventory has ranged from 271.11 to 937.65. According to the industry distribution chart, Biofrontera AG ranks #889 out of 918 companies in the Drug Manufacturers industry, placing it in the top 96.8%.
Is Biofrontera AG's Days Inventory too high?
Biofrontera AG's current Days Inventory of 472.66 is near median its 10-year median of 438.45. Over the past 10 years, this metric has ranged from a low of 271.11 to a high of 937.65. The Drug Manufacturers industry median Days Inventory is 164.43. Biofrontera AG's value of 472.66 is 187.5% above this industry median. Based on the distribution chart, Biofrontera AG ranks #889 out of 918 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Biofrontera AG has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofrontera AG ranks #889 out of 918 companies for Days Inventory. This places Biofrontera AG in the lower half of its industry. The industry median Days Inventory is 164.43. Biofrontera AG's value of 472.66 is 187.5% above this benchmark. Historically, Biofrontera AG's own Days Inventory has ranged from 271.11 to 937.65 over the past decade. While the company's 10-year median is 438.45 vs. the industry median of 164.43, Biofrontera AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.43, based on 918 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofrontera AG's current Days Inventory of 472.66 is 187.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Biofrontera AG and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofrontera AG's current Days Inventory is 472.66, which is near median its own 10-year median of 438.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Biofrontera AG (BIFRF) has a current Days Inventory of 472.66. The stock's GF Value™ is $31.34, compared to a current price of $22.68 — trading 27.6% below its estimated fair value. The current Days Inventory is 472.66, which is near median its 10-year median of 438.45 and 187.5% above the Drug Manufacturers industry median of 164.43. Biofrontera AG's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Biofrontera AG (BIFRF), the current Days Inventory is 472.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera AG (BIFRF) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued.
The current stock price of $22.68 is trading 27.6% below its estimated GF Value™ of $31.34.
Key valuation signals for BIFRF:
Days Inventory: 472.66 (near median its 10-year median of 438.45)
GF Value™: $31.34 vs. price of $22.68 (27.6% below fair value)
Industry Position: 187.5% above the Drug Manufacturers median (#889 of 918)
No single metric tells the full story. See the BIFRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
58GF Score
Get the complete analysis for BIFRF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIFRF has been successfully added to your 
